信立泰(002294.SZ)擬2.41億元分階段受讓蘇州信立泰15.73%股權
格隆匯4月10日丨信立泰(002294.SZ)公佈，公司擬與信立泰(蘇州)藥業有限公司(“蘇州信立泰”)股東蘇州香塘創業投資有限責任公司(“蘇州香塘”)、自然人股東彭紅衞、趙斌、楊偉、王舸、張寶華、談義良等簽訂股權轉讓協議，以自籌資金人民幣2.41億元，分階段受讓蘇州信立泰少數股東15.73%股權。受讓前，公司持有蘇州信立泰84.27%股權，受讓完成後，公司將持有蘇州信立泰100%股權。
信立泰(蘇州)藥業有限公司經營範圍：基因工程藥物的生產、銷售；藥品、化粧品、保健食品的研發及技術服務和技術轉讓；(依法須經批准的項目，經相關部門批准後方可開展經營活動)。
蘇州信立泰是公司旗下重要的生物藥物產業化基地，擁有產業化基地 60畝，建築面積約26,000平方米，建有蘇州市重組蛋白藥物工程技術研究中心，具備原核生產線、真核生產線、製劑生產線及質量檢測平台、技術轉移平台，可同時進行產品的產業化轉移和商業化生產，加速研發生產進程，並能滿足未來多年產能需求。500L發酵規模的重組蛋白藥物生產平台，兼容大腸桿菌和酵母菌的表達體系，能滿足多肽、生產因子類基因工程產品的生產；真核生產線採用GE可拋型生物製藥生產線——規模為2000L的Flex Factory™的生物製藥整體解決方案，可快速實現產品間的換產；製劑生產平台可滿足凍乾粉針、西林瓶水針、卡氏瓶、預灌封瓶的生產。
蘇州信立泰產品管線豐富，在骨質疏鬆、內分泌等領域均有創新生物藥或生物類似物佈局，形成完善的產品梯隊，具有強大的預期收益能力。隨着新產品的推廣及在研項目的陸續上市，將為公司帶來新的業績增長點。
此次受讓蘇州信立泰少數股東股權的金額為人民幣2.41億元，佔公司2019年度經審計總資產的3.12%，不會影響公司現金流的正常運轉，亦不會影響公司的生產經營，對公司本期和未來財務狀況和經營成果不存在不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
